The National Institute for Health and Clinical Excellence (NICE) has announced that because insufficient evidence was provided by the manufacturers, it is unable to recommend the use of the following treatments on the NHS:
Bevacizumab in combination with paclitaxel for the first-line treatment of metastatic breast cancer.
Bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with inoperable advanced, metastatic or recurrent non-smallcell lung cancer (other than predominantly squamous cell histology).
Carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme (a type of brain cancer) for whom surgery is appropriate.
Cetuximab for the treatment of colorectal cancer following failure of oxaliplatin-containing chemotherapy.
Chief executive Andrew Dillon said: “Timely guidance to the NHS relies on the manufacturer to submit evidence so that we can appraise the treatment. Occasionally, manufactures either fail to make a submission or the submission is inadequate.
“Of course, if sufficient evidence does become available in the future, we may take the opportunity to review and to revise our advice to the NHS.”
Copyright PA Business 2008